p53 alteration independently predicts poor outcomes in patients with endometrial cancer: A clinicopathologic study of 131 cases and literature review

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 533-538

  Lee, Eun Ju ^a   Kim, Tae Joong ^b   Kim, Dae Shick ^b   Choi, Chel Hun ^b   Lee, Jeong Won ^b   Lee, Je Ho ^b   Bae, Duk Soo ^b   Kim, Byoung Gie ^b  

^a Chung Ang University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Endometrial Cancer; p53

Indexed keywords

PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MEDICAL RECORD; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ENDOMETRIAL NEOPLASMS; EXONS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 75749149679     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.11.018     Document Type: Article

References (39)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 59 (2009) 225-249
2. Baak J.P., Snijders W., van Diermen B., van Diest P.J., Diepenhorst F.W., and Benraadt J. Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in international Federation of gynecology and obstetrics stage 1 and 2 endometrial carcinoma. J. Clin. Oncol. 21 (2003) 4214-4221
3. Miller D.S., and King L.P. Gynecologic oncology group trials in uterine corpus malignancies: recent progress. J. Gynecol. Oncol. 19 (2008) 218-222
4. Mariani A., Webb M.J., Keeney G.L., Lesnick T.G., and Podratz K.C. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol. Oncol. 87 (2002) 274-280
5. Lane D.P. Benchimol S. p53: oncogene or anti-oncogene?. Genes Dev. 4 (1990) 1-8
6. Levine A.J., Momand J., and Finlay C.A. The p53 tumour suppressor gene. Nature 351 (1991) 453-456
7. Hollstein M., Sidransky D., and Vogelstein B. Harris CC. p53 mutations in human cancers. Science 253 (1991) 49-53
8. Finlay C.A., Hinds P.W., Tan T.H., Eliyahu D., Oren M., and Levine A.J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol. 8 (1988) 531-539
9. Kraiss S., Spiess S., Reihsaus E., and Montenarh M. Correlation of metabolic stability and altered quaternary structure of oncoprotein p53 with cell transformation. Exp. Cell Res. 192 (1991) 157-164
10. Davidoff A.M., Humphrey P.A., Iglehart J.D., and Marks J.R. Genetic basis for p53 overexpression in human breast cancer. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 5006-5010
11. Iggo R., Gatter K., Bartek J., Lane D., and Harris A.L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335 (1990) 675-679
12. Kohler M.F., Berchuck A., Davidoff A.M., Humphrey P.A., Dodge R.K., Iglehart J.D., et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res. 52 (1992) 1622-1627
13. Creasman W.T. New gynecologic cancer staging. Obstet. Gynecol. 75 (1990) 287-288
14. Ozalp S., Yalcin O.T., Tanir H.M., Kabukcuoglu S., and Erol G. p53 overexpression as a prognostic indicator in endometrial carcinoma. Eur. J. Gynaecol. Oncol. 24 (2003) 275-278
15. Erdem O., Erdem M., Dursun A., Akyol G., and Erdem A. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables. Int. J. Gynecol. Pathol. 22 (2003) 254-260
16. Lundgren C., Auer G., Frankendal B., Moberger B., Nilsson B., and Nordstrom B. Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma. Int. J. Gynecol. Cancer 12 (2002) 110-118
17. Osmanagaoglu M.A., Kadioglu S., Osmanagaoglu S., Bozkaya H., Reis A., and Tekelioglu Y. The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma. Eur. J. Gynaecol. Oncol. 26 (2005) 64-70
18. Soong R., Knowles S., Williams K.E., Hammond I.G., Wysocki S.J., and Iacopetta B.J. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br. J. Cancer 74 (1996) 562-567
19. Strang P., Nordstom B., Nilsson S., Bergstrom R., and Tribukait B. Mutant p53 protein as a predictor of survival in endometrial carcinoma. Eur. J. Cancer 32A (1996) 598-602
20. Engelsen I.B., Stefansson I., Akslen L.A., and Salvesen H.B. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am. J. Obstet. Gynecol. 195 (2006) 979-986
21. Oreskovic S., Babic D., Kalafatic D., Barisic D., and Beketic-Oreskovic L. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol. Oncol. 93 (2004) 34-40
22. Sherman M.E., and Bur M.E. Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum. Pathol. 26 (1995) 1268-1274
23. Kohler M.F., Carney P., Dodge R., Soper J.T., Clarke-Pearson D.L., Marks J.R., et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am. J. Obstet. Gynecol. 175 (1996) 1246-1252
24. Koul A., Bendahl P.O., Borg A., Ferno M., Lidebring M.F., Hogberg T., et al. TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer. Int. J. Gynecol. Cancer 12 (2002) 362-371
25. Shih H.C., Shiozawa T., Kato K., Imai T., Miyamoto T., Uchikawa J., et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum. Pathol. 34 (2003) 471-478
26. Suzuki C., Matsumoto T., Sonoue H., Arakawa A., Furugen Y., and Kinoshita K. Prognostic significance of the infiltrative pattern invasion in endometrioid adenocarcinoma of the endometrium. Pathol. Int. 53 (2003) 495-500
27. Jeon Y.T., Kang S., Kang D.H., Yoo K.Y., Park I.A., Bang Y.J., et al. Cyclooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiol. Biomarkers Prev. 13 (2004) 1538-1542
28. Dupont J., Wang X., Marshall D.S., Leitao M., Hedvat C.V., Hummer A., et al. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol. Oncol. 94 (2004) 449-455
29. Athanassiadou P., Athanassiades P., Grapsa D., Gonidi M., Athanassiadou A.M., Stamati P.N., et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int. J. Gynecol. Cancer 17 (2007) 697-704
30. Pansare V., Munkarah A.R., Schimp V., Haitham Arabi M., Saed G.M., Morris R.T., et al. Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas. Mod. Pathol. 20 (2007) 35-43
31. Saffari B., Bernstein L., Hong D.C., Sullivan-Halley J., Runnebaum I.B., Grill H.J., et al. Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. Int. J. Gynecol. Cancer 15 (2005) 952-963
32. Sakuragi N., Watari H., Ebina Y., Yamamoto R., Steiner E., Koelbl H., et al. Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer. Int. J. Cancer 116 (2005) 514-519
33. Koul A., Borg A., Pejovic T., Bendahl P.O., Hogberg T., Iosif C.S., et al. Identification of TP53 gene mutations in uterine corpus cancer with short follow-up. Gynecol. Oncol. 67 (1997) 295-302
34. Kihana T., Hamada K., Inoue Y., Yano N., Iketani H., Murao S., et al. Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. Cancer 76 (1995) 72-78
35. Jones M.W., Kounelis S., Hsu C., Papadaki H., Bakker A., Swalsky P.A., et al. Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison. Int. J. Gynecol. Pathol. 16 (1997) 354-360
36. Wachtel S.S., Wachtel G., Shulman L.P., Phillips O., Miller B., and Photopulos G. Identification of p53 mutations in endometrial adenocarcinoma by polymerase chain reaction-single-strand conformation polymorphism. J. Soc. Gynecol. Investig. 1 (1994) 234-237
37. Lax S.F., Kendall B., Tashiro H., Slebos R.J., and Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88 (2000) 814-824
38. Sarnow P., Ho Y.S., Williams J., and Levine A.J. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28 (1982) 387-394
39. Fujino M., Dosaka-Akita H., Kato M., Kinoshita I., Akie K., and Kawakami Y. Simultaneous use of the PCR-SSCP method and immunohistochemistry for increasing the detection efficacy of p53 abnormalities in human lung cancer. Am. J. Clin. Pathol. 104 (1995) 319-324